Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,034,809

« Back to Dashboard

Which drugs does patent 8,034,809 protect, and when does it expire?


Patent 8,034,809 protects STRIVERDI RESPIMAT and STIOLTO RESPIMAT and is included in two NDAs.

This patent has nineteen patent family members in eighteen countries.

Summary for Patent: 8,034,809

Title:Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Abstract: Enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Inventor(s): Lustenberger; Philipp (Basel, CH), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:12/335,076
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes8,034,809► Subscribe TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
Boehringer Ingelheim
STIOLTO RESPIMAT
olodaterol hydrochloride; tiotropium bromide
SPRAY, METERED;INHALATION206756-001May 21, 2015RXYesYes8,034,809► Subscribe TREATMENT OF COPD
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,034,809

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 024 454May 14, 2004

Non-Orange Book Patents for Patent: 8,034,809

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,220,742Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments► Subscribe
7,491,719Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,034,809

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2562859► Subscribe
China101133039► Subscribe
China102827097► Subscribe
China106146425► Subscribe
Germany102004024454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot